These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 35608264)

  • 1. The use of whole-body MRI in multiple myeloma.
    Portet M; Owens E; Howlett D
    Clin Med (Lond); 2019 Jul; 19(4):355-356. PubMed ID: 31308125
    [No Abstract]   [Full Text] [Related]  

  • 2. Challenges in designing and running smouldering myeloma interventional clinical trials.
    Lecat C; Boyle EM; Hughes D; Lee L; Smith D; Bygrave C; Ramasamy K; Yong K
    EJHaem; 2024 Apr; 5(2):418-420. PubMed ID: 38633110
    [No Abstract]   [Full Text] [Related]  

  • 3. Risk stratification models overestimate progression risk in contemporary patients with smoldering multiple myeloma.
    Mellgard G; Gilligan M; Cliff ERS; Bhutani D; Mohyuddin GR; Eisenberger A; Lentzsch S; Chakraborty R
    Hemasphere; 2024 Mar; 8(3):e61. PubMed ID: 38510991
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinician preferences on treatment of smoldering myeloma: a cross-sectional survey.
    Mohyuddin GR; Chakraborty R; Cliff ERS; Derman BA
    EClinicalMedicine; 2023 Nov; 65():102272. PubMed ID: 38046471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Presenting Symptoms in Newly Diagnosed Myeloma, Relation to Organ Damage, and Implications for Symptom-Directed Screening: A Secondary Analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) Trial.
    Bowcock S; Atkin C; Iqbal G; Pratt G; Yong K; Neal RD; Planche T; Karunanithi K; Jenkins S; Stern S; Arnott S; Toth P; Wandroo F; Dunn J; Drayson MT;
    Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is aggressive treatment of smoldering myeloma the path to curing myeloma?
    Chakraborty R; Al Hadidi S; Cliff ERS; Mohyuddin GR
    Blood Adv; 2023 Aug; 7(15):3932-3935. PubMed ID: 37196639
    [No Abstract]   [Full Text] [Related]  

  • 7. Test-retest, inter- and intra-rater reproducibility of size measurements of focal bone marrow lesions in MRI in patients with multiple myeloma.
    Wennmann M; Grözinger M; Weru V; Hielscher T; Rotkopf LT; Bauer F; Gnirs R; Nonnenmacher T; Sauer S; Goldschmidt H; Weinhold N; Bonekamp D; Weber TF; Schlemmer HP; Delorme S
    Br J Radiol; 2023 Apr; 96(1145):20220745. PubMed ID: 37001052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Smoldering multiple myeloma.
    Gao M; Yang G; Kong Y; Wu X; Shi J
    Biomed Res Int; 2015; 2015():623254. PubMed ID: 26000300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent Advances in the Management of Smoldering Multiple Myeloma.
    Madhira BR; Konala VM; Adapa S; Naramala S; Ravella PM; Parikh K; Gentile TC
    World J Oncol; 2020 Apr; 11(2):45-54. PubMed ID: 32284772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole-body magnetic resonance imaging plus serological follow-up for early identification of progression in smouldering myeloma patients to prevent development of end-organ damage.
    Wennmann M; Goldschmidt H; Mosebach J; Hielscher T; Bäuerle T; Komljenovic D; McCarthy PL; Merz M; Schlemmer HP; Raab MS; Sauer S; Delorme S; Hillengass J
    Br J Haematol; 2022 Oct; 199(1):65-75. PubMed ID: 35608264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spatial Distribution of Focal Lesions in Whole-Body MRI and Influence of MRI Protocol on Staging in Patients with Smoldering Multiple Myeloma According to the New SLiM-CRAB-Criteria.
    Wennmann M; Hielscher T; Kintzelé L; Menze BH; Langs G; Merz M; Sauer S; Kauczor HU; Schlemmer HP; Delorme S; Goldschmidt H; Weinhold N; Hillengass J; Weber MA
    Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32906608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma.
    Merz M; Hielscher T; Wagner B; Sauer S; Shah S; Raab MS; Jauch A; Neben K; Hose D; Egerer G; Weber MA; Delorme S; Goldschmidt H; Hillengass J
    Leukemia; 2014 Sep; 28(9):1902-8. PubMed ID: 24535407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value of whole body MRI and dynamic contrast enhanced MRI in the diagnosis, follow-up and evaluation of disease activity and extent in multiple myeloma.
    Dutoit JC; Vanderkerken MA; Verstraete KL
    Eur J Radiol; 2013 Sep; 82(9):1444-52. PubMed ID: 23726124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mode of progression in smoldering multiple myeloma: a study of 406 patients.
    Abdallah NH; Lakshman A; Kumar SK; Cook J; Binder M; Kapoor P; Dispenzieri A; Gertz MA; Lacy MQ; Hayman SR; Buadi FK; Dingli D; Lin Y; Kourelis T; Warsame R; Bergsagel L; Rajkumar SV
    Blood Cancer J; 2024 Jan; 14(1):9. PubMed ID: 38228628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma.
    Gavriatopoulou M; Βoultadaki A; Koutoulidis V; Ntanasis-Stathopoulos I; Bourgioti C; Malandrakis P; Fotiou D; Migkou M; Kanellias N; Eleutherakis-Papaiakovou E; Kastritis E; Terpos E; Dimopoulos MA; Moulopoulos LA
    Blood Cancer J; 2020 Sep; 10(9):93. PubMed ID: 32978365
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.